zintick

AbbVie ABBV

AbbVie Inc. · NYSE · Pharmaceutical Preparations

$294.89+1.41%close on Oct. 30, 2026 · volume 6.9M · Yahoo Finance

Price, last 49 sessions

$260.00$280.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 30, 2026 · high $294.89 · low $247.26 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Aug. 14, 2026Nicholas Donoghoe
EVP, CHIEF BUS/STRAT OFFICER
Sold32,710$250.00$8.18 million

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 13 →
  • 8-KOct. 30, 2026, 7:51 a.m. ETView on SEC.govOur explainer

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedAbbVie Q3 2026 adjusted EPS $3.82 beats $3.77 consensus on $17.404 billion revenue; full-year adjusted EPS guidance raised to $13.95-$13.99

  • 8-KOct. 15, 2026, 4 p.m. ETView on SEC.gov

    Departure/appointment of directors or officers

  • 8-KOct. 5, 2026, 4:07 p.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

  • 4Oct. 2, 2026, 5 p.m. ETView on SEC.gov
  • 4Oct. 2, 2026, 5 p.m. ETView on SEC.gov
  • 8-KSept. 3, 2026, 8:47 a.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

  • 4Aug. 18, 2026, 5 p.m. ETView on SEC.gov
  • 8-KAug. 18, 2026, 4:30 p.m. ETView on SEC.gov

    Other events · Financial statements and exhibits